Calls for FDA transparency rise
A research firm urged greater transparency around the FDA’s accelerated‑approval pathway amid ongoing questions over safety and efficacy, arguing that the process needs clearer disclosure. The call adds to regulatory scrutiny that could affect how clinical programs and associated testing workflows are managed. (reuters.com)
The Institute for Clinical and Economic Review said on April 16 that the Food and Drug Administration still discloses too little about why it grants accelerated approval to some drugs. (icer.org) Accelerated approval is the FDA’s faster route for drugs for serious diseases, letting companies win clearance on a stand-in measure — such as tumor shrinkage — before proving patients live longer or feel better. The tradeoff is that drugmakers must run follow-up studies to confirm the benefit. (fda.gov) ICER and Verdant Research said their April 2026 white paper was based on literature review, stakeholder interviews and revisions after a December 2025 policy summit. The paper called for clearer public explanations of FDA decisions, stronger evidence standards and better communication of risks and uncertainty to doctors and patients. (icer.org) The pressure comes after Congress tightened the pathway in the Food and Drug Omnibus Reform Act, which was signed on December 29, 2022. That law gave the FDA added tools tied to confirmatory trials and required new public reports and other documents. (fda.gov) The FDA followed with draft guidance published in January 2025 on when a confirmatory trial counts as “underway” before an accelerated approval decision. The agency said the changes were meant to help ensure those post-approval studies are completed on time. (fda.gov) ICER’s report says the remaining gap is not just speed, but visibility: patients, payers and clinicians often cannot see how much uncertainty the FDA accepted or why one surrogate endpoint was persuasive and another was not. ICER President Sarah Emond said the pathway has produced “several successes” but also “regulatory inconsistency” and delayed confirmatory evidence. (icer.org) That debate has practical consequences for companies running clinical programs. If the FDA expects earlier, better-designed confirmatory trials and fuller public disclosure, sponsors may need to lock in study plans, data collection and testing workflows sooner. (fda.gov; icer.org) ICER did not call for ending accelerated approval. Its April 16 paper framed the issue as unfinished oversight of a pathway that still gives patients earlier access to medicines while leaving key questions to be answered after launch. (icer.org)
